

Polymorphism in bordetella pertussis virulence factors in serbia before switch from whole cell to a cellular pertussis vaccine

Abstract

Background: Mass vaccination has significantly reduced the incidence of pertussis; however, the disease is re-emerging even in some countries with high vaccination coverage. In Serbia, whole cell *pertussis* vaccine was introduced in 1957 and it has been used since 2014.

Methods: To monitor changes in bacterial population, 77 isolates collected from 1953 to 2013 were studied. The methods included serotyping of fimbriae (Fim), genotyping of pertactin (prn), *pertussis* toxin S1 subunit (ptxA) and pulsed-field gel electrophoresis analysis (PFGE).

Results: Shift from ptxA2 to ptxA1 has been observed in isolates since the late of 1960s. In the period 1961-1979 genotype ptxA1 became as common as genotype ptxA2. After that, during the period of 1980-1989, the predominant ptx genotype was ptxA1. Re-appearance of the ptxA2 allele followed an addition of the two strains harboring ptxA1 in the vaccine in 1985. The allele prn1 was predominant among the Serbian isolates, though prn3 and prn11 have been detected since 1981. The prn2 allele was only found in one strain isolated in 1984, two of the four strains isolated in 2000 and three strains from 2011. Serotype Fim2.3 disappeared before 1980 and serotype Fim2 became predominant since then. The four vaccine strains represented four PFGE profiles. Twenty-two (40%) isolates tested by PFGE produced 22 distinct profiles. Twenty-four (43%) isolates had unique Serbian profiles (BpSBR).

Conclusion: The results of this present study indicate that the *B. pertussis* population in Serbia is different from other vaccinated populations and that this difference may be related to the vaccine used for 57 years.

Keywords: *bordetella pertussis*, *pertussis* toxin, pertactin, pfge, serotyping, fimbriae, electrophoresis

Volume 3 Issue 1 - 2016

Tatjana Pljesa,^{1,2} Qiushui He,³ Gordana Dakic,² Mirjana Vignjevic-Krastavcevic,² Ivana Cirkovic⁴

¹Public Health Institute of Belgrade, Serbia

²Institute of Virology, Serbia

³National Institute for Health and Welfare (THL), Finland

⁴University of Belgrade, Serbia

Correspondence: Tatjana Pljesa, Public Health Institute of Belgrade, Belgrade, Serbia, Tel +381 642777386, Email tanjapljesa@hotmail.com

Received: July 08, 2016 | **Published:** November 18, 2016

Abbreviations: Fim, fimbriae; prn, pertactin; PFGE, pulsed-field gel electrophoresis analysis; DTPw, diphtheria-tetanus-whole cell *pertussis*; ptxA, *pertussis* toxin subunit

Introduction

Pertussis (whooping cough) is a worldwide infectious disease caused by the bacteria *Bordetella pertussis*.¹ Despite the fact that the introduction of vaccination in the 1950s and 1960s has reduced *pertussis* morbidity and mortality, this disease is still prevalent² and *pertussis* is still one of the leading causes of vaccine preventable deaths in the world.³ *Pertussis* is a respiratory tract infection transmitted by aerial droplets with an incubation period of 7-10 days, which remains contagious for up to 3 weeks after the appearance of the first signs if no treatment is given. Mass vaccination has significantly reduced the incidence of *pertussis*; however, the disease is re-emerging even in some countries with high vaccination coverage. The resurgence of *pertussis* in countries, such as the Netherlands, the United States, Canada and Australia, has been studied to find an explanation for its re-emergence.^{2,4-7} Moreover, in these countries antigenic divergence with respect to *pertussis* toxin (Ptx) and pertactin (Prn) has been found between *Bordetella pertussis* vaccine strains and clinical isolates. In Serbia vaccination against *pertussis* has been from 1957. The diphtheria-tetanus-whole cell *pertussis* (DTPw) vaccine has been manufactured in the Institute

of Virology, Vaccine and Sera Torlak, Belgrade, Serbia. The DTPw vaccine was given at 2, 4, 6, and 12 months of age. A second booster dose with the mono *pertussis* vaccine was given at 4 years of age during the periods from 1970 to 1981 and from 1990 to 2000. Last composition of the whole-cell vaccine has been used since 1985 and contained four *B. pertussis* strains. The vaccine strains were chosen in compliance with serotype, immunogenicity and specific toxicity. The four strains represented three serotypes: Fim2 (8/84), Fim2,3 (1772/57 and 2047/57) and Fim3 (23/81). The vaccine strains 2047/57 and 1772/57 represented ptxA2/prn1 genotypes, whereas the vaccine strains 23/81 and 8/84 harbor ptxA1/prn1 and ptxA1/prn2. All vaccine strains were in equal amount in the vaccine composition.⁸ The reported vaccination coverage in Serbia ranged from 79% to 98% (median, 90%) in 1981-2013.³ In Serbia, the whole-cell *pertussis* vaccine has been replaced with a cellular vaccine in 2014. The aim of this study was to analyze *B. pertussis* isolates circulating between 1953 and 2013 in Serbia by standard typing methods⁹ and to compare them with those circulating in other European countries, USA and Australia.

Materials and methods

B. pertussis strains and patient information

This study included 77 *B. pertussis* isolates. Detailed information on each of vaccine strains and clinical isolates was included in the Supplementary data. Clinical isolates were selected from the *B.*

pertussis strain collection of the Institute of Virology, Vaccine and Sera Torlak, Belgrade, Serbia. Information on age, gender and vaccination was available in 64 patients. Their age ranged from 2 months to 33 years (mean, 6.06 years; median, 5 years). Bacteria were grown at 36°C for 72 h on Bordet Gengou agar supplemented with 30% defibrinated sheep blood and subcultured on the same medium for 24 h.¹⁰




Figure 1 The incidence (cases per 100,000) of reported *pertussis* cases in Serbia between 1965 and 2011. Source: Infectious Disease Register, Institute of Public Health of Serbia "Dr Milan Jovanovic Batut".




Figure 2 The frequency of Fim2, Fim2.3, and Fim3 serotypes of *B. pertussis* isolates circulating in Serbia.

Fimbriae serotyping of *B. pertussis* isolates

Serotyping was performed with monoclonal antibodies against Fim2 and Fim3 by slide agglutination test.^{9,11}

Genotyping of Ptx S1 subunit (ptxA) and prn

The standardized genotyping of Ptx S1 subunit (ptxA) and prn was performed by sequencing and Light Cycler PCR.¹¹⁻¹³ These methods have been recommended for the epidemiological typing of *B. pertussis* isolates.⁹

PFGE analysis

For the PFGE analysis, six international reference strains were included⁹ and nomenclature was based on the defined profiles already observed in Finland (BpFINR) and Sweden (BpSR).^{11,12} Profiles assigned BpSBR have been found only among the Serbian isolates analyzed.

Statistical analysis

A chi-square test was used to compare frequencies of strain genotypes and serotypes between four time-periods (1953-1960, 1961-1979, 1980-1989 and 1990-2013). A p -value ≤ 0.05 was considered as statistically significant. Selection of time-periods was performed according to the epidemiological data.

Results

Epidemiology of pertussis in Serbia

In Serbia, *pertussis* is a notifiable infectious disease, which is collected in the Infectious Disease Register of the National Public Health Institute. The incidence of *pertussis* in Serbia has been decreasing since the introduction of vaccination at the end of the 1950s and beginning of the 1960s (Figure 1). All isolates prior to 1960 were recovered from unvaccinated patients. In the period 1980-1989, 82.35 % of patients were vaccinated while there were 64.3% of vaccinated patients in the period 1990-2013. There were no epidemiological data for strains isolated from patients in period 1960-1979.

Fimbriae serotyping

All three serotypes, Fim2, Fim2.3, and Fim3, were observed among the clinical isolates. The frequency of each serotype has changed over time. Before the introduction of vaccination, the prevalent serotypes were Fim 2(38%) and Fim 2.3(62%). After the introduction of vaccination, the frequency of serotype Fim2.3 decreased, being significantly lower, 0% in 1980-1989 and 23% in 1990-2013, compared to those observed in 1953-1960 and 1961-1979 ($P = 0.00013$ and 0.0003) (Table 1). Although the serotype Fim3 started to appear, Fim2 has been the most prevalent serotype during the study period (Figure 2).

Genotypes of ptxA and prn

All strains isolated from 1953 to 1960 were ptxA2 genotype. Shift from ptxA2 to ptxA1 has been observed in isolates since the late of 1960s. In the period 1961-1979 genotype ptxA1 became as common as genotype ptxA2. After that, during the period of 1980-1989, the predominant ptx genotype was ptxA1 (91.2%). Re-appearance of the isolates containing ptxA2 was noticed after the two strains harboring ptxA1 were added into the vaccine in 1985.⁸ During the period of 1990-2013, both ptxA genotypes were present in the population (Figure 3).




Figure 3 The frequency of ptxA1 and ptxA2 genotypes of *B. pertussis* isolates circulating in Serbia.

In the first two observed periods, 1953-1960 and 1960-1979, all isolated strains were prn1 genotype. Although the allele prn1 was mostly predominant among the Serbian isolates analyzed, prn2, prn3 and prn11 occurred in some isolates since 1980s and finally prn2 genotype became predominant in the period 1990-2011. The allele prn3 and prn11 were first detected in 1981 and 1984, respectively and became more frequent in 1990-2013. The prn2 allele was only found in one strain isolated in 1984, two of the four strains isolated in 2000 and three strains from 2011. The frequency of prn1 in 1953-1960 and

1961-1979 was significantly higher than those observed in 1980-1989 and 1990-2013 ($P < 0.001$ in both groups) (Table 1 & Figure 4). The frequency of *prn11* in 1980-1989 and 1990-2013 was significantly higher than that found in 1953-1960 and 1961-1979 ($P < 0.001$ in both groups).




Figure 4 The frequency of *prn* genotypes of *B. pertussis* isolates circulating in Serbia.




Figure 5 Dendrogram analysis of PFGE profiles of *B. pertussis* Serbian vaccine strains and their relatedness to isolates groups. The unweighted pair group method using arithmetic averages (UPGMA) with 1% band tolerance and 1% optimisation settings was used as the clustering method.




Figure 6 Dendrogram analysis of 22 PFGE profiles of *B. pertussis* isolates circulating in Serbia during 1953-2014. The unweighted pair group method using arithmetic averages (UPGMA) with 1% band tolerance and 1% optimisation settings was used as the clustering method. The symbol O indicates international reference strains and / Serbian vaccine strains. Of the isolates with identical profiles, only first one is shown.

All the four isolates harboring *prn3* contained *ptxA1*, whereas five of the six isolates harboring *prn11* represented *ptxA2*. All the six isolates harboring *prn11* were serotype Fim2, whereas three of the four isolates harboring *prn3* were serotype Fim3.

PFGE profiles

The four vaccine strains represented four PFGE profiles (Figure 5). The 56 isolates tested by PFGE produced 22 distinct profiles (Figure 6). The five common profiles represented about two thirds of isolates (17 isolates with BpSR23, eight with BpFINR1, five with BpFINR9, four with BpSBR6 and three with BpSBR5). Twenty-four (43%) isolates had unique Serbian profiles (BpSBR). Change in PFGE profiles was observed over time. All PFGE profiles, except BpSR23, observed in 1950s disappeared since then. The profile BpSR23 was found in all the study periods. Of the 56 isolates tested by PFGE, 53 (95%) belonged to two clusters, having a high similarity with a minimum of 78% overall relatedness (Figure 6). Of the six isolates harboring *prn11*, four had the profile BpSBR6, one had BpSBR7, and one had BpSBR14. They all fell into the same cluster. Of the four isolates harboring *prn3*, two had the profile BpSBR8, one had BpSBR12, and one had BpSR127. They all fell into another cluster. Two isolates with *prn2* had the profiles BpSBR9 and BpSR11. They fell into the same cluster as the isolates with *prn3*.

Discussion

Vaccinations with Pw vaccines were introduced in the 1940s to 1960s and have successfully reduced morbidity and mortality of *pertussis* throughout the world.¹⁴ Pw vaccines have been produced by different manufacturers, and the *B. pertussis* vaccine strains vary. The vaccine strains, both for whole-cell and cellular vaccines were usually isolated in the 1940s to 1960s, and in many countries the vaccinations have selected circulating isolates dissimilar to the vaccine strains.^{4,12,15,16} Further, resurgence of *pertussis* has been observed in countries with long term *pertussis* vaccination.^{7,16-19} In Serbia Pw vaccine has been in use from 1957 to 2014, and was manufactured in the Institute of Virology, Vaccines and Sera Torlak, Belgrade. In contrast to the many other countries, the Serbian vaccine contained four strains: two isolated in 1950s and two in 1980s. Of the four strains, one strain represented *prn2* genotype and the other three *prn1* genotype. The vaccine has remained unchanged since 1985, when the two newly isolated strains have been added to the vaccine composition. One of the added strains was strain 8/84 with *prn2* allele.⁸ This unique formulation of the Serbian Pw vaccine provided us an opportunity to study possible effect of the inclusion of “contemporary” strains in the vaccine on temporal trends in *B. pertussis* population. The finding that frequency of the Serbian isolates representing *prn2* was low and its appearance was late is striking. Polymorphism in *Prn* is essentially limited to region 1 and is located adjacent to an RDG motif implicated in adhesion.²⁰ So far, 13 *prn* alleles have been identified.²¹ In many countries the allele *prn1* or *prn7* is present in most vaccine strains and predominated in prevaccine era.¹⁴ However, the “vaccine type” strains were gradually replaced by “non-vaccine type” strains mainly *prn2* after the introduction of vaccination. The *prn2* is by far the most prevalent type in modern isolates.^{4,11,12,16,22-24} Depending on the time when the *pertussis* vaccination was started and the potency of vaccine used, in most countries isolates containing *prn2* were first observed in the 1970s to 1980s.^{4,9,11,12,23,25} In line with these observations, in Serbia one isolate (8/84) harboring *prn2* was detected in 1984. The isolate was added in vaccine composition in 1985. After that, all isolates were *prn1* or *prn11* until 2000 when two out of four isolates contained the *prn2* allele. The low frequency of *prn2* strains and their relatively late

emergence in Serbia may be due to the fact that the vaccine contained an isolate having *prn2* allele. In this present study, four different *prn* alleles (*prn1*, *prn2*, *prn3* and *prn11*) were detected among the Serbian isolates. The alleles *prn1* to *prn3* have been observed in many countries.^{4,12,22-24,26} The allele *prn11* was only reported in a recent study carried out in Australia, where all 5 strains containing *prn11* were isolated in the same year (1982) and in the same region.²⁶ In our study, however, the 6 *prn11* isolates were detected in different years from 1984 to 2000. Of the six isolates, four had identical serotype and *ptxA* genotype. The difference between *Prn1* and *Prn11* was only one repeat in region 1: *Prn1* has five repeats, whereas *Prn11* has six repeats. These observations that most of the isolates from 1980 to 2013 contained the *prn1* or *prn11* allele suggested that the strains prevalent in the pre-vaccine era are still circulating in Serbia. The Serbian vaccine strains do not contain the allele *prn3*. However, strains harboring the allele *prn3* were not isolated in the study at a frequency comparable to that seen in other countries.^{12,22,24,26} The exact reasons for the difference are not known. In addition to the vaccine composition, many factors such as immunity, density and dynamics of population can contribute to selection of the circulating strains. So far 8 *ptxA* alleles have been reported.²¹ In most countries, the allele *ptxA2* and/or *ptxA3* are present in most vaccine strains and predominated in the isolates circulating in pre-vaccine era.^{4,12,16,23} However, the “vaccine type” strains were gradually replaced by “non-vaccine” type *ptxA1* after the vaccination was introduced. Our result was in agreement with the earlier studies. Shift from *ptxA2* to *ptxA1* was observed in isolates since the late of 1960s, and predominant *ptxA* genotype in the period 1980-1989 was *ptxA1*. Interestingly, re-appearance of the *ptxA2* allele followed an addition of the two strains harboring *ptxA1* in the vaccine composition in 1985. After that moment, there were more *ptxA2* isolates than previously. The high frequency of strains harboring *ptxA2* in 1990-2013 was not comparable to that noticed in many other countries.^{4,12,23} Several studies have shown that *Fim2*

isolates predominate in unvaccinated population, while they are largely displaced by *Fim3* strains when vaccination is introduced with a Pw vaccine containing both *Fim2* and *Fim3*.^{27,28} Although the vaccination has been used in Serbia since 1957, nearly half of the isolates studied from 1957 to 2013 were serotype *Fim2*. Increases in the incidence of *pertussis* have been reported in many countries with long vaccination history. Moreover, in many of these countries divergence between vaccine strains and circulating isolates have been found. Interestingly, the incidence of *pertussis* has been decreasing in Serbia during observed period. It is known that in vaccinated populations, symptoms of *pertussis* can be mild and the patients do not usually seek for medical help. Therefore, the possibility that incidence of *pertussis* is underestimated in this country cannot be excluded. Whether the low incidence of *pertussis* in this country is related to the vaccine used remains to be illustrated. King et al.,²⁹ were the first to show that variation in *Prn* affects vaccine efficacy in the mouse model.²⁹ It has been recently shown that the adequate bacterial elimination rates were observed in mice immunized and challenged with the same vaccine type strain³⁰ and that the vaccine prepared from a recent isolate provided the highest mouse protection when compared to those prepared from the old isolates such as the strain Tohama I.³¹ The question of whether *prn2* strains eventually became predominant in this country remains to be shown in further investigations. According to the observed findings, *B. pertussis* population in Serbia during observed period was different from other vaccinated populations and this difference may be related to the vaccine used. The effects of cellular vaccines on the circulating *B. pertussis* strains should be closely monitored. This study lays a good background for further monitoring of the circulating *B. pertussis* isolates in Serbia. The exceptionally stable vaccination history with a high vaccination coverage rate makes Serbia a good location for monitoring of the changes in the *B. pertussis* population after the introduction of a new vaccination program with cellular *pertussis* vaccines in 2014.

Table 1 Temporal trends in serotypes and genotypes of pertussis toxin and pertactin in Serbia

Year of Isolation	No of Isolates	ptxA (no)		prn (no)				serotype (no)		
		ptxA1	ptxA2	prn1	prn2	prn3	prn11	Fim2	Fim2,3	Fim3
1953-1960	21	0	21	21	0	0	0	8	13	0
1961-1979	9	4	5	9	0	0	0	0	6	3
1980-1989	34	31	3	27	1	3	3	22	0	12
1990-2014	13	10	3	4	5	1	3	7	3	3
Total	77	45	32	61	6	4	6	37	22	18

Acknowledgments

None.

Conflicts of interest

Author declares there are no conflicts of interest.

Funding

None.

References

1. Miller JF, Johnson SA, Black WJ, et al. Constitutive sensory transduction mutations in the *Bordetella pertussis* *bvgS* gene. *J Bacteriol*. 1992;174(3):970-979.
2. Mattoo S, Cherry JD. Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to *Bordetella pertussis* and other *Bordetella* subspecies. *Clin Microbiol Rev*. 2005;18(2):326-382.
3. WHO. immunization, vaccination and biologicals. Vaccine preventable diseases Vaccines monitoring system Global Summary Reference Time Series: SERBIA. *World Health Organisation*, Switzerland. 2012.
4. Cassidy P, Sanden G, Heuvelman K, et al. Polymorphism in *Bordetella pertussis* pertactin and *pertussis* toxin virulence factors in the United States, 1935-1999. *J Infect Dis*. 2000;182(5):1402-1408.
5. Byrne S, Slack AT. Analysis of *Bordetella pertussis* pertactin and *pertussis* toxin types from Queensland, Australia, 1999-2003. *BMC Infect Dis*. 2006;6:53.
6. de Greeff SC, Mooi FR, Westerhof A, et al. *Pertussis* disease burden in the household: how to protect young infants. *Clin Infect Dis*. 2010;50(10):1339-1345.
7. Celentano LP, Massari M, Paramatti D, et al. Resurgence of *pertussis* in Europe. *Pediatr Infect Dis J*. 2005;24(9):761-765.
8. Dakic G, Kallonen T, Elomaa A, et al. *Bordetella pertussis* vaccine strains and circulating isolates in Serbia. *Vaccine*. 2010;28(5):1188-1192.

9. Mooi FR, Hallander H, Konig WCH, et al. Epidemiological typing of *Bordetella pertussis* isolates: recommendations for a standard methodology. *Eur J Clin Microbiol Infect Dis*. 2000; 19(3):174–181.
10. Bouchez V, Caro V, Levillain E, et al. Genomic content of *Bordetella pertussis* clinical isolates circulating in areas of intensive children vaccination. *PLoS One*. 2008;3(6):e2437.
11. Advani A, Donnelly D, Hallander H. Reference system for characterization of *Bordetella pertussis* pulsed-field gel electrophoresis profiles. *J Clin Microbiol*. 2004;42(7):2890–2897.
12. Elomaa A, Advani A, Donnelly D, et al. Strain variation among *Bordetella pertussis* isolates in Finland, where the whole-cell *pertussis* vaccine has been used for 50 years. *J Clin Microbiol*. 2005;43(8):3681–3687.
13. Heikkinen E, Xing DK, Olander RM, et al. *Bordetella pertussis* isolates in Finland: serotype and fimbrial expression. *BMC Microbiol*. 2008;8:162.
14. He Q, Mertsola J. Factors contributing to *pertussis* resurgence. *Future Microbiol*. 2008;3(3):329–339.
15. Mooi FR, He Q, van Oirschot H, et al. Variation in the *Bordetella pertussis* virulence factors *pertussis* toxin and pertactin in vaccine strains and clinical isolates in Finland. *Infect Immun*. 1999;67(6):3133–3134.
16. Kallonen T, Hannuksela GYK, Elomaa A, et al. Differences in the genomic content of *Bordetella pertussis* isolates before and after introduction of *pertussis* vaccines in four European countries. *Infect Gen and Evol*. 2011;11(8):2034–2042.
17. Halperin SA. The control of *pertussis*-2007 and beyond. *N Engl J Med*. 2007;356(2):110–113.
18. McIntyre P, Gidding H, Gilmour R, et al. Vaccine preventable diseases and vaccination coverage in Australia, 1999 to 2000. *Commun Dis Intell Suppl-Supplxi*. 2002;1–111.
19. Mooi FR, van Loo IH, King AJ. Adaptation of *Bordetella pertussis* to vaccination: a cause for its reemergence? *Emerg Infect Dis*. 2001;7(3):526–528.
20. Leininger E, Roberts M, Kenimer JG, et al. Pertactin, an Arg-Gly-Asp-containing *Bordetella pertussis* surface protein that promotes adherence of mammalian cells. *Proc Natl Acad Sci USA*. 1991;88(2):345–349.
21. Mooi FR. *Bordetella pertussis* and vaccination: The persistence of a genetically monomorphic pathogen. *Infect Genet Evol*. 2010;10(1):36–49.
22. Mooi FR, van Oirschot H, Heuvelman K, et al. Polymorphism in the *Bordetella pertussis* virulence factors P.69/pertactin and *pertussis* toxin in The Netherlands: temporal trends and evidence for vaccine driven evolution. *Infect Immun*. 1998;66(2):670–675.
23. Weber C, Eude BC, Coralie G, et al. Polymorphism of *Bordetella pertussis* isolates circulating for the last 10 years in France, where a single effective whole-cell vaccine has been used for more than 30 years. *J Clin Microbiol*. 2001;39(12):4396–4403.
24. Njamkepo E, Cantinelli T, Guigon G, et al. Genomic analysis and comparison of *Bordetella pertussis* isolates circulating in low and high vaccine coverage areas. *Microbes Infect*. 2008;10(14–15):1582–1586.
25. Hallander HO, Advani A, Donnelly D, et al. Shifts of *Bordetella pertussis* variants in Sweden from 1970 to 2003, during three periods marked by different vaccination programs. *J Clin Microbiol*. 2005;43(6):2856–2865.
26. Poynten M, McIntyre PB, Mooi FR, et al. Temporal trends in circulating *Bordetella pertussis* strains in Australia. *Epidemiol Infect*. 2004;132(2):185–193.
27. Hallander H, Advani A, Riffelmann M, et al. *Bordetella pertussis* strains circulating in Europe in 1999 to 2004 as determined by pulsed-field gel electrophoresis. *J Clin Microbiol*. 2007;45(10):257–262.
28. Preston NW, Carter EJ. Serotype specificity of vaccine-induced immunity to *pertussis*. *Communicable disease report*. 1992;2(13):R155–156.
29. King AJ, Berbers G, van Oirschot HF, et al. Role of the polymorphic region 1 of the *Bordetella pertussis* protein pertactin in immunity. *Microbiology*. 2001;147(11):2885–2895.
30. Bottero D, Gaillard ME, Fingerhann M, et al. Pulsed-field gel electrophoresis, pertactin, *pertussis* toxin S1 subunit polymorphisms, and surfaceome analysis of vaccine and clinical *Bordetella pertussis* strains. *Clin Vaccine Immunol*. 2007;14(11):1490–1498.
31. Pereira A, Pereira AS, Filho MCA, et al. Comparative analysis of a *Bordetella pertussis* patient isolated strain and classical strains used in the *pertussis* vaccine. *Vaccine*. 2005;23(34):4353–4358.